"Weight-loss drug manufacturer Eli Lilly has taken aim at the government, claiming the UK is probably the worst country in Europe for medicine pricing. Dave Ricks, chief executive of the firm that makes Mounjaro, told the Financial Times that the UK pays less than other nations for its products and added, unless that changes, I don't think they will see many new medicines and I don't think they will see much investment."
"The comments come amid a spate of disappointing announcements from pharmaceutical firms, including Merck withdrawing from a planned $1bn research hub and London-listed firm AstraZeneca pausing investment on a 200m site in Cambridge. Eli Lilly is a $700bn (520bn) company based in the US which, along with diabetes drug Mounjaro, also makes products across a wide spectrum, including for obesity, autoimmune disease and Alzheimer's."
The Independent sends journalists to cover developing stories across reproductive rights, climate change and Big Tech, and relies on donations to fund on-the-ground reporting without paywalls. Eli Lilly has criticized the UK as probably the worst country in Europe for medicine pricing, with chief executive Dave Ricks saying lower UK prices reduce new medicines and investment. The comments follow disappointing industry decisions, including Merck withdrawing from a planned $1bn research hub and AstraZeneca pausing investment on a 200m Cambridge site. Eli Lilly, a $700bn (520bn) US company, objects to the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), which requires firms to repay part of drug sales revenue to the NHS.
Read at www.independent.co.uk
Unable to calculate read time
Collection
[
|
...
]